<p></p><p class="" style="margin: 0cm 0cm 0.0001pt; word-break: keep-all; text-align: justify; line-height: 115%; font-size: 10pt; font-family: &quot;맑은 고딕&quot;;"><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">On March 18, Samsung C&amp;T has decided to participate in Samsung Biologics' paid-in capital increase and acquire 1,904,239 shares.<o:p></o:p></span></p> <p class="" style="margin: 0cm 0cm 0.0001pt; word-break: keep-all; text-align: justify; line-height: 115%; font-size: 10pt; font-family: &quot;맑은 고딕&quot;;"><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;"><o:p>&nbsp;</o:p></span></p> <p class="" style="margin: 0cm 0cm 0.0001pt; word-break: keep-all; text-align: justify; line-height: 115%; font-size: 10pt; font-family: &quot;맑은 고딕&quot;;"><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;"><span style="mso-spacerun:yes">&nbsp;</span>- Number of Shares to be Acquired: 1,904,239 (KRW 1,216,808,721,000)<o:p></o:p></span></p> <p class="" style="margin: 0cm 0cm 0.0001pt; text-indent: 6pt; word-break: keep-all; text-align: justify; line-height: 115%; font-size: 10pt; font-family: &quot;맑은 고딕&quot;;"><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">- Scheduled Acquisition Date: April 16, 2022<o:p></o:p></span></p> <p class="" style="margin: 0cm 0cm 0.0001pt; text-indent: 6pt; word-break: keep-all; text-align: justify; line-height: 115%; font-size: 10pt; font-family: &quot;맑은 고딕&quot;;"><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">- Number of Shares Held after Acquisition: 30,646,705 (43.06%)<o:p></o:p></span></p><br><p></p>